Approaches to Drug Pharmacokinetics Study Design in Preclinical Trials (Review)

INTRODUCTION. According to drug registration requirements, a registration dossier should include the data on preclinical trials of drug pharmacokinetics. However, the scope of data provided for various drugs groups, as well as pharmacokinetics elements to be studied at each stage of the product life cycle is still a relevant issue.

AIM. This study aimed to analyze literature data, Russian and foreign guidelines on preclinical trials of drug pharmacokinetics to choose an optimal strategy of data collection at various stages of drug life cycle.

DISCUSSION. The research materials included regulatory documents, guidelines on preclinical trials, scientific articles and other publicly available sources (including electronic RSCI databases (eLIBRARY.RU), PubMed, and Web of Science). We analyzed the main approaches to planning pharmacokinetic trials for various drugs (original, generic, biological drugs, etc.), including the type and number of laboratory animals, the doses studied and the time points of biomaterial sampling.

CONCLUSIONS. Preclinical pharmacokinetic trials are warranted for optimization of active pharmaceutical substance molecules, selection of the dosage form to study various drug groups, predicting pharmacokinetic parameters in humans, reducing time costs and risks when developing safe and effective drugs. Designs of pharmacokinetic trials were proposed at the stage of molecule screening, molecule optimization and selection of the drug forms for the research of various drug groups.

1. Bem AE, Kasimova AR, Gomon YuM, Kolbin AS. The concept of target-mediated drug distribution of high-molecular and low-molecular compounds. Drug Bulletin. 2021;15(3):3–12 (In Russ.). EDN: XJMBJD

2. Rajput YK, Sahu TK. Pharmacokinetic consideration in drug development: A review. Hist Med. 2022;8(2):441–60.

3. Morgan P. The use of preclinical pharmacokinetic and pharmacodynamic data to predict clinical doses: current and future perspectives. International Congress Series. 2001;1220:1– 12. https://doi.org/10.1016/S0531-5131(01)00282-5

4. Zherdev VP, Boyko SS, Shevchenko RV, Gudasheva TA. The role of pharmacokinetics and biopharmaceutical investigations in the creation of a new dipeptide drugs (experimental investigation). Pharmacokinetics and Pharmacodynamics. 2017;(1):3–10 (In Russ.). EDN: YPJQTV

5. Kolyvanov GB, Bochkov PO, Litvin AA, et al. Absolute bioavailability of a substance with cardioprotective activity (ALM-802) in rats. Pharmacokinetics and Pharmacodynamics. 2021;(2):31–5 (In Russ.). https://doi.org/10.37489/2587-7836-2021-2-31-35

6. Abaimov DA, Khutorova AV, Sariev AK, et al. The pilot study of the basic pharmacokinetic properties of pyrrolylcarnosine — the new pyrrolic derivative of dipeptide carnosine. Pharmacokinetics and Pharmacodynamics. 2023;(2):29–36 (In Russ.). https://doi.org/10.37489/2587-7836-2023-2-29-36

7. Genatullina GN, Yasenyavskaya AL, Tsibizova AA, Samotrueva MA. Nanoencapsulated systems: Promising biomedical initiatives in pharmacology. Antibiotics and Chemotherapy. 2024;69(3–4):62–72 (In Russ.). https://doi.org/10.37489/0235-2990-2024-69-3-4-62-72

8. Yadav КS, Soni G, Choudhary D, et al. Microemulsions for enhancing drug delivery of hydrophilic drugs: Exploring various routes of administration. Med Drug Discov. 2023;20:100162. https://doi.org/10.1016/j.medidd.2023.100162

9. Haripriyaa M, Suthindhiran K. Pharmacokinetics of nanoparticles: Current knowledge, future directions and its implications in drug delivery. Futur J Pharm Sci. 2023;9:113. https://doi.org/10.1186/s43094-023-00569-y

10. Lai Y, Chu X, Di L, et al. Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development. Acta Pharm Sin B. 2022;12(6): 2751–77. https://doi.org/10.1016/j.apsb.2022.03.009

11. Hushpulian DM, Gaisina IN, Nikulin SV, et al. High throughput screening in drug discovery: Problems and solutions. Vestn. Mosk. un-ta. Ser. 2. Chemistry. 2024;65(2):96–112 (In Russ.). EDN: ARAUPF

12. Sandhya K, Ramesh Y, Penabaka V, Chandra YP. The role of pharmacokinetics in drug development. GSC Biol Pharm Sci. 2025;30(3):322–8. https://doi.org/10.30574/gscbps.2025.30.3.0098

13. Reichel A, Lienau P. Pharmacokinetics in drug discovery: An exposure-centred approach to optimising and predicting drug efficacy and safety. In: Nielsch U, Fuhrmann U, Jaroch S, eds. Handbook of Experimental Pharmacology. Springer; 2016. https://doi.org/10.1007/164_2015_26

14. Ruiz-Garcia A, Bermejo M, Moss A, Casabo VG. Pharmacokinetics in drug discovery. J Pharm Sci. 2008;97(2):654–90. https://doi.org/10.1002/jps.21009

15. White RE. High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery. Annu Rev Pharmacol Toxicol. 2000;40:133–57. https://doi.org/10.1146/annurev.pharmtox.40.1.133

16. Li Y, Meng Q, Yang M, et al. Current trends in drug metabolism and pharmacokinetics. Acta Pharm Sin B. 2019;9(6): 1113–44. https://doi.org/10.1016/j.apsb.2019.10.001

17. Rizk ML, Zou L, Savic RM, Dooley KE. Importance of drug pharmacokinetics at the site of action. Clin Transl Sci. 2017;10(3):133–42. https://doi.org/10.1111/cts.12448

18. Daina A, Michielin O, Zoete V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7:42717. https://doi.org/10.1038/srep42717

19. Tuntland T, Ethell B, Kosaka T, et al. Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research. Front Pharmacol. 2014;5:174. https://doi.org/10.3389/fphar.2014.00174

20. Zhang X, Zhou B, Gong Y, Liu Y. Investigation into the pharmacodynamics and pharmacokinetics of recombinant human interferon alfa-2b vaginal suppository following process optimization in Chinese rhesus macaque. Sci Rep. 2025; 15(1):15932. https://doi.org/10.1038/s41598-025-98813-3

21. Demina NB, Bardakov AI, Krasniuk II. Formation and development of the biopharmaceutical doctrine of creating effective medicines. Pharmacy. 2022;71(7):5–10 (In Russ.). https://doi.org/10.29296/25419218-2022-07-01

22. Samojlov VM, Savitskii MV, Romashkina AG, et al. Pharmacokinetics of solid dispersion and cristalline forms of the anti-virulence drug fluorothiazinon in rats. Medical & Pharmaceutical Journal “Pulse”. 2023;25(7):57–62 (In Russ.). https://doi.org//10.26787/nydha-2686-6838-2023-25-7-57-62

23. More SK, Pawar AP. Preparation, optimization and preliminary pharmacokinetic study of curcumin encapsulated turmeric oil microemulsion in zebra fish. Eur J Pharm Sci. 2020;155(1):105539. https://doi.org/10.1016/j.ejps.2020.105539

24. Ali SK, Al-Akkam EJ. Comparison of pharmacokinetic characteristics of bilosomal dispersion versus pure solution of oral ropinirole hydrochloride in rats. J Fac Med Baghdad. 2024;66(2): 201–8. https://doi.org/10.32007/jfacmedbagdad.6622210

25. Kravtsova OYu, Dvoryaninov DA, Kolyvanov GB, et al. Experimental pharmacokinetics of a new antiparkinsonian drug ADK-1113. Pharmacokinetics and Pharmacodynamics. 2024;(1):27–31 (In Russ.). https://doi.org/10.37489/2587-7836-2024-1-27-31

26. Boyko SS, Koliasnikova KN, Zherdev VP. Comparative study of pharmacokinetics and enzymatic resistance of the neuroprotective mean GZK-111 and noopept in rats. Pharmacokinetics and Pharmacodynamics. 2022;(3):20–5 (In Russ.). https://doi.org/10.37489/2587-7836-2022-3-20-25

27. Lu W, Zeng R, Pan M, et al. Pharmacokinetics, bioavailability, and tissue distribution of MRTX1133 in rats using UHPLC-MS/MS. Front Pharmacol. 2024;15:1509319. https://doi.org/10.3389/fphar.2024.1509319

28. Wilson SE, Carpenter JW, Gardhouse S, Kukanich B. Pharmacokinetics of mavacoxib in New Zealand White rabbits (Oryctolagus cuniculus). Am J Vet Res. 2023;84(5):ajvr.22.11.0196. https://doi.org/10.2460/ajvr.22.11.0196

29. Kumar PV, Maki MAA, Wei YS, et al. Rabbit as an animal model for pharmacokinetics studies of enteric capsule contains recombinant human keratinocyte growth factor loaded chitosan nanoparticles. Curr Clin Pharmacol. 2019;14(2):132–40. https://doi.org/10.2174/1574884714666181120103907

30. Shevchenko RV, Litvin AA, Kolyvanov GB, et al. The pharmacokinetics of the injectable dosage form of GK-2 in rabbits. Pharmacokinetics and Pharmacodynamics. 2020;(2):17–21 (In Russ.). https://doi.org/10.37489/2587-7836-2020-2-17-21

31. Weir SJ, Wood R, Schorno K, et al. Preclinical pharmacokinetics of fosciclopirox, a novel treatment of urothelial cancers, in rats and dogs. J Pharmacol Exp Ther. 2019;370(2):148–59. https://doi.org/10.1124/jpet.119.257972

32. Xie H, Chung J-K, Mascelli MA, McCauley TG. Pharmacokinetics and bioavailability of a therapeutic enzyme (idursulfase) in cynomolgus monkeys after intrathecal and intravenous administration. PLoS One. 2015;10(4):e0122453. https://doi.org/10.1371/journal.pone.0122453

33. Engalycheva GN, Syubaev RD, Relevant species selection for preclinical safety studies of medicines: A review. Safety and Risk of Pharmacotherapy. 2025;13(1):31–43 (In Russ.). https://doi.org/10.30895/2312-7821-2025-460

34. Miroshnikov MV, Sultanova KT, Makarova MN, Makarov VG. A comparative review of the activity of enzymes of the cytochrome P450 system in humans and laboratory animals. Prognostic value of preclinical models in vivo. Translational Medicine. 2022;9(5):44–77 (In Russ.). https://doi.org/10.18705/2311-4495-2022-9-5-44-77

35. Heller AA, Lockwood SY, Janes TM, Spence DM. Technologies for measuring pharmacokinetic profiles. Annu Rev Anal Chem (Palo Alto Calif). 2018;11(1):79–100. https://doi.org/10.1146/annurev-anchem-061417-125611

36. Zherdev VP, Boyko SS, Shevchenko RV, et al. The role of studies of interspecies differences pharmacokinetics in the creation of new peptide drugs. Pharmacokinetics and Pharmacodynamics. 2018;(1):3-23 (In Russ.). https://doi.org/10.24411/2587-7836-2018-10001

37. Zheng M-C, Tang W-T, Yu L-L, et al. Preclinical pharmacokinetics and bioavailability of oxypeucedanin in rats after single intravenous and oral administration. Molecules. 2022;27(11):3570. https://doi.org/10.3390/molecules27113570

38. Kosman VM, Karlina MV. Retrospective of pharmacokinetic parameters variability in dependence on biological species and number of individuals in the experimental group. Laboratory Animals for Science. 2023;6(1):60–9 (In Russ.). https://doi.org/10.57034/2618723X-2023-01-06

39. Czerniak R. Gender-based differences in pharmacokinetics in laboratory animal models. Int J Toxicol. 2001;20(3):161–3. https://doi.org/10.1080/109158101317097746

40. Kushida H, Matsumoto T, Ikarashi Y, et al. Gender differences in plasma pharmacokinetics and hepatic metabolism of geissoschizine methyl ether from Uncaria hook in rats. J Ethnopharmacol. 2021;264:113354. https://doi.org/10.1016/j.jep.2020.113354

41. Arora P, Gudelsky G, Desai PB. Gender-based differences in brain and plasma pharmacokinetics of letrozole in Sprague-Dawley rats: Application of physiologically-based pharmacokinetic modeling to gain quantitative insights. PLoS One. 2021;16(4):e0248579. https://doi.org/10.1371/journal.pone.0248579

42. Smol’yakova VI, Chernysheva GA, Yanovskaya EA, et al. Evaluation of the linearity of pharmacokinetics of the phenolic antioxidant 4-methyl-2,6-diisobornylphenol upon intragastric administration. Experimental and Clinical Pharmacology. 2014;77(2):31–4 (In Russ.). EDN: SVVPPT

43. Kravtsova OYu, Kolyvanov GB, Litvin AA, et al. Evaluation of the linearity of neuroprotector GZK-111 pharmacokinetic. Experimental and Clinical Pharmacology. 2023;86(3):8–11 (In Russ.). https://doi.org/10.30906/0869-2092-2023-86-01-8-11

44. Anizan S, Concheiro M, Lehner KR, et al. Linear pharmacokinetics of 3,4-methylenedioxypyrovalerone (MDPV) and its metabolites in the rat: relationship to pharmacodynamic effects. Addict Biol. 2014;21(2):339–47. https://doi.org/10.1111/adb.12201

45. Shang H, Dai X, Li M, et al. Absolute bioavailability, dose proportionality, and tissue distribution of rotundic acid in rats based on validated LC-QqQ-MS/MS method. J Pharm Anal. 2022;12(2):278–86. https://doi.org/10.1016/j.jpha.2021.03.008

46. Kolyvanov GB, Litvin AA, Kravtsova OYu, et al. Pharmacokinetics of a potential antiepileptic drug GIZh-298. Pharmacokinetics and Pharmacodynamics. 2024;(2):57–61 (In Russ.). https://doi.org/10.37489/2587-7836-2024-2-57-61

47. Cook CS, Zhang L, Ames GB, et al. Single- and repeated-dose pharmacokinetics of eplerenone, a selective aldosterone receptor blocker, in rats. Xenobiotica. 2003;33(3):305–21. https://doi.org/10.1080/0049825021000049277

48. Bochner F, Hooper WD, Tyrer JH, Eadie MJ. Factors involved in an outbreak of phenytoin intoxication. J Neurol Sci. 1972;16(4):481–7. https://doi.org/10.1016/0022-510x(72)90053-6

49. Silva DA, Löbenberg R, Davies N. Are excipients inert? Phenytoin pharmaceutical investigations with new incompatibility insights. J Pharm Pharm Sci. 2018;21(1s):29745. https://doi.org/10.18433/jpps29745

50. Thakur SK, Pal R, Pandey P, et al. Approaches of drug-excipients interaction in pharmaceutical drug product formulation. World J Pharm Res. 2023;12(2):347–66.

51. Gawari ShD, Kambale HV, Satpute VM, et al. A review: drug-excipient interactions study. Int J Novel Res Devel. 2023:8(2):b641–51.

52. Panakanti R, Narang AS. Impact of excipient interactions on drug bioavailability from solid dosage forms. Pharm Res. 2012:29(10):2639–59. https://doi.org/10.1007/s11095-012-0767-8

53. Kovalskaya GN, Zhukova DYa, Mikhalevich EN. Interaction of medicines for injections and infusions. Siberian Medical Review. 2018;(6):12–21 (In Russ.). https://doi.org/10.20333/2500136-2018-6-12-21

54. Logunova IV, Bogomolova NS, Chistyakov VV. Experimental study of bioavailability of the combination drug of Dioxazid. Pharmacokinetics and Pharmacodynamics. 2012;(1):29–32 (In Russ.). EDN: RWVVCV

55. Yu DA, You M, Ji WW, et al. Preclinical pharmacokinetics of a recombinant humanized rabbit anti-VEGF monoclonal antibody in rabbits and monkeys. Toxicol Lett. 2018;292:73–7. https://doi.org/10.1016/j.toxlet.2018.04.031

56. Sherstoboev EYu, Oleinik LA, Zhdanov VV, et al. Pharmacokinetic parameters of oral pegylated IFN-λ1. Bull Exp Biol Med. 2022;173(2):215–218 (In Russ.). https://doi.org/10.1007/s10517-022-05521-3

57. Cai Y, Zhang Z, Fan K, et al. Pharmacokinetics, tissue distribution, excretion, and antiviral activity of pegylated recombinant human consensus interferon-α variant in monkeys, rats and guinea pigs. Regulatory Peptides. 2012;173(1–3): 74–81. https://doi.org/10.1016/j.regpep.2011.09.008

58. Smirnov VV, Petukhova OA, Filatov AV, et al. Studying the pharmacokinetics of biotechnological medicinal products on the example of monoclonal antibodies. Biological Products. Prevention, Diagnosis, Treatment. 2023;23(2):173–80 (In Russ.). https://doi.org/10.30895/2221-996X-2023-23-2-173-180

59. Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol. 2017;6(9):576–88. https://doi.org/10.1002/psp4.12224

60. Derkaev AA, Ryabova EI, Esmagambetov IB, et al. A modified single-domain antibody candidate for the treatment of botulism caused by botulinum toxin type A. Biological Products. Prevention, Diagnosis, Treatment. 2025;25(1):58–70 (In Russ.). https://doi.org/10.30895/2221-996X-2025-591

61. Astapova OV, Berchatova AA. Gene therapy medicinal products: Non-clinical safety studies. Safety and Risk of Pharmacotherapy. 2023;11(1):73–96 (In Russ.). https://doi.org/10.30895/2312-7821-2023-11-1-329

62. Kopein DS, Poroshin GN, Khamitov RA. Implementation of the quality-by-design concept for an adeno-associated viral vector-based gene therapy. Biological Products. Prevention, Diagnosis, Treatment. 2025;25(2):141–55 (In Russ.). https://doi.org/10.30895/2221-996X-2025-580

63. Alyautdin RN, Romanov BK, Pereverzev AP, et al. Alipogene tiparvovec: A long journey of risk-benefit ratio assessment of gene therapy products. Scientific Centre for Expert Evaluation of Medicinal Products Bulletin. 2015;(1):31–4 (In Russ.). EDN: UBDTJH

64. Rachinskaya OA, Melnikova EV, Merkulov VA. The aspects of manufacturing and quality control of somatic medications based on mesenchymal stem cells. Antibiotics and Chemotherapy. 2025;70(1–2):58–75 (In Russ.). https://doi.org/10.37489/0235-2990-2025-70-1-2-58-75

65. Galitsyna EV, Kulikova EA, Pavelyev YuA, et al. Cell-based medicinal products: A review of current research. Biological Products. Prevention, Diagnosis, Treatment. 2024;24(4):428–42 (In Russ.). https://doi.org/10.30895/2221-996X-2024-557

66. Wang X, Guo J, Deng X, et al. Evaluation of pharmacokinetics and toxicology of biosimilar APZ001 antibody in Macaca cynomolgus. Trop J Pharm Res. 2018;17(9):1885–91. https://doi.org/10.4314/tjpr.v17i9.30

67. Podolyakina AI, Dmitrieva AA, Postnikova VA, et al. Pharmacokinetics of pertuzumab biosimilar compared with the original drug in cynomolgus monkeys. Russian Journal of Oncology. 2024;29(3):160–70 (In Russ.). https://doi.org/10.17816/onco636526

68. Olefir YuV, Medunitsyn NV, Avdeeva ZhI, et al. Modern biological/biotechnological medicinal products. Topical issues and prospects for development. BIOpreparations. Prevention, Diagnosis, Treatment. 2016;16(2):67–77 (In Russ.). EDN: WAIVUX

69. McLachlan AJ, Adiwidjaja J. Pharmacokinetics of biologics. In: Ramzan I, ed. Biologics, biosimilars, and biobetters: An introduction for pharmacists, physicians and other health practitioners. John Wiley & Sons; 2020. https://doi.org/10.1002/9781119564690.ch8

70. Maksimkina EA, Kudrin A, Aladysheva ZhI, et al. State regulation of similar biologic drugs for medical use in the European Union. Remedium. 2013;(7–8):60–1 (In Russ.). EDN: QZIHKN

71. Lugovik IA, Babina AV, Arutyunyan SS, et al. The first generic tirzepatide GP30931: Physicochemical and biological similarity to the reference drug. Drug Development & Registration. 2025;14(2):54–74 (In Russ.). https://doi.org/10.33380/2305-2066-2025-14-2-2084

72. Breder VV. Biopharmaceuticals in oncology: New horizons, but old problems. Oncohematology. 2007;(4):78–83 (In Russ.). EDN: MSMSBN